Search
Pegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[L44667] Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
Products: ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML, Oncaspar 750 U/ml powder for solution for injection/infusionOxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigationalOngoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. … [A797] Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal
Products: hovid Oxaliplatin 50mg Powder for Concentrate for Solution for Infusion, hovid Oxaliplatin 100mg Powder for Concentrate for Solution for InfusionClarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with am...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: KLACID GRANULES FOR ORAL SUSPENSION, KLACID IV FOR INJECTION 500 mg/vialNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. … Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody InteractionsProducts: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, Opdivo 10mg/ml, Concentrate for solution for infusionErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalIn particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor [FDA Label]. … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsProducts: AIMOVIG (140 MG/ML SOLUTION FOR INJECTION), AIMOVIG (70 MG/ML SOLUTION FOR INJECTION)Tedizolid
go.drugbank.com/drugs/DB14569ApprovedInvestigationalThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: SIVEXTRO LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION 200MG PER VIALBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigationalBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...
Products: Retrox 3.5mg Powder for Solution for Injection, BORTESUN POWDER FOR SOLUTION FOR INJECTION 3.5 mgCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalFDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Products: KYPROLIS POWDER FOR SOLUTION FOR INFUSION 60MG/VIAL, KYPROLIS POWDER FOR SOLUTION FOR INFUSION 30 MG/VIALTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigationalagonist for this indication. … Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor
Categories: Glucose-dependent Insulinotropic Polypeptide Receptor AgonistProducts: Mounjaro 5 mg solution for injection in vial, Mounjaro 10 mg solution for injection in vialTuroctocog alfa
go.drugbank.com/drugs/DB09109ApprovedTuroctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally
Products: NovoEight 500IU Powder and Solvent for Solution for Injection, NovoEight 1000IU Powder and Solvent for Solution for Injection